Hygeia Hospital
- Address
- 4 Erithrou Stavrou st., Marousi, GR 151 23 Athens, Greece
Hygeia Hospital - Breast Cancer Research Center
Hygeia Hospital is a leading clinical research institution specializing in personalized oncology care, with particular expertise in breast cancer treatment strategies. The center focuses on integrating advanced molecular diagnostics into clinical decision-making to optimize treatment outcomes for women with early-stage breast cancer.
- Personalized treatment strategies using gene expression profiling (Prosigna®) for chemotherapy decision-making
- High-risk hormone receptor-positive, HER2-negative breast cancer in premenopausal women
- Optimal endocrine therapy combined with tailored adjuvant chemotherapy approaches
The hospital's research program emphasizes precision medicine approaches for young women with early breast cancer, particularly those with complex risk profiles involving lymph node involvement or larger tumor sizes. Through their participation in pivotal clinical trials, Hygeia Hospital investigates whether molecular diagnostics can safely guide treatment de-escalation strategies, aiming to spare appropriate patients from unnecessary chemotherapy while maintaining excellent invasive breast cancer-free survival outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Unicancer1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hygeia Hospital
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Gene Expression-Driven Adjuvant Chemotherapy Versus Standard Care in Premenopausal HR-Positive/HER2-Negative Breast Cancer Using Paclitaxel and Drug Combination | Unicancer | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 1 | Unknown | 2026-04-23 | 2026-04-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.